Five Food Supplement Advertisements Prohibited Over Misleading Women's Health Assertions
Advertisements for five distinct food supplement brands have been officially banned by the Advertising Standards Authority (ASA) due to making deceptive claims regarding their effectiveness in addressing women's health issues. The banned ads pertain to products from 222 Balance Me, Lunera, Minerva, Nova Menopause Vitality, and PolyBiotics, all of which were found to have violated advertising regulations by asserting capabilities to prevent, treat, or cure conditions such as menopause symptoms and polycystic ovary syndrome (PCOS).
Detailed Examination of Misleading Assertions
The ASA conducted a thorough investigation into these advertisements, which were identified as potentially exploiting individuals' health anxieties, emotional distress, or financial vulnerabilities. Utilizing artificial intelligence to scrutinize health-related claims in online ads, the authority uncovered persistent and emerging patterns of misleading information, directly influencing its decisions to prohibit these supplements. According to the ASA, numerous claims within the ads were deemed "unacceptable" and not only breached multiple regulatory rules but also posed risks of misleading susceptible consumers or diverting them from seeking proper medical guidance.
Specifically, ads for 222 Balance Me, Lunera, Minerva, and Nova Menopause Vitality inaccurately suggested that their products could alleviate or manage symptoms associated with menopause. Meanwhile, an advertisement and website for PolyBiotics implied that its supplements could prevent, cure, or treat PCOS, a complex hormonal disorder. The ASA emphasized that such claims are strictly prohibited for food supplements, which are not authorized to make medicinal assertions.
Responses from the Companies Involved
In response to the ASA's findings, 222 Collective, the company behind 222 Balance Me, acknowledged that the wording in their ads might have "inadvertently implied" therapeutic benefits for symptoms like PMS, menopause-related issues, anxiety, bloating, heavy bleeding, or mood disorders. The firm described itself as a new, founder-operated small business that is still familiarizing itself with advertising regulations and is collaborating with Trading Standards to avoid making explicit or implied treatment claims in the future.
Lunera accepted that consumers would interpret their claims as attributing medicinal properties to a food supplement, admitting that such assertions should not have been published. PolyBiotics similarly conceded that references to PCOS, ovulation, fertility, cycle regulation, insulin resistance, and related symptoms constituted disease treatment or symptom-management claims, which are not permitted under current regulations. Notably, Minerva and Nova did not respond to the ASA's inquiries regarding the banned advertisements.
Official Statements and Ongoing Monitoring
Catherine Drewett, investigations manager at the ASA, highlighted the importance of accurate information in women's health, stating, "People deserve clear and accurate information. Ads making misleading claims about treating symptoms of the menopause, PCOS and other hormonal conditions can cause real harm and today's rulings hold advertisers to account." She further assured that the ASA will continue to closely monitor this sector and encouraged individuals with concerns about advertisements to report them for review.
This action underscores the ASA's commitment to protecting consumers from false advertising, particularly in sensitive health areas where misinformation can lead to significant harm. The rulings serve as a reminder to advertisers to adhere strictly to regulatory standards and avoid making unsubstantiated health claims that could mislead vulnerable populations.
